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Area Under the Curve Bioequivalence of Mycophenolate Mofetil:
CellCept® vs Generic
Abstract
Therapeutic drug monitoring (TDM) of mycophenolate mofetil (MMF) has been investigated using multiple
linear regression (MLR) and bayesian pharmacokinetics (BAY) independently. Some studies have shown that
therapeutic drug monitoring (TDM) of MMF via measuring area under the curve (AUC) may decrease risk
of rejection as well as toxicity. Between May 2008 and June 2009, the FDA granted approval to 7 different
manufacturers of generic MMF. Secondary to the between-patient and within-patient variability of MMF
pharmacokinetics, it is important to use validated MLR and BAY models. These models have thus far been
designed using only CellCept®. In this study, MLR and BAY models are used to evaluate the bioequivalence of
mycophenolic acid (MPA) AUC of CellCept® (innovator MMF) compared to generic MMF (manufactured
by Mylan) in renal transplant (RT) recipients. Four of 6 patients had generic MMF AUC levels within 90% -
110% AUC of innovator, and 5 of 6 patients had levels within 80 - 125%. Current MLR and BAY models
might not be applicable to patients taking generic MMF.
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Abstract
Therapeutic drug monitoring (TDM) of mycophenolate mofetil (MMF) has been 
investigated using multiple linear regression (MLR) and bayesian pharmacokinetics 
(BAY) independently. Some studies have shown that therapeutic drug monitoring 
(TDM) of MMF via measuring area under the curve (AUC) may decrease risk of 
rejection as well as toxicity.  Between May 2008 and June 2009, the FDA granted 
approval to 7 different manufacturers of generic MMF.  Secondary to the between-
patient and within-patient variability of MMF pharmacokinetics, it is important to 
use validated MLR and BAY models.  These models have thus far been designed 
using only CellCept®.  In this study, MLR and BAY models are used to evaluate the 
bioequivalence of mycophenolic acid (MPA) AUC of CellCept® (innovator MMF) 
compared to generic MMF (manufactured by Mylan) in renal transplant (RT) 
recipients. Four of 6 patients had generic MMF AUC levels within 90% - 110% AUC 
of innovator, and 5 of 6 patients had levels within 80 - 125%. Current MLR and BAY 
models might not be applicable to patients taking generic MMF.
Introduction
Mycophenolate mofetil is an immunosuppressant medication used to prevent 
rejection in kidney transplantation. The standard dose of MMF is 1000 mg twice 
Results Discussion
The FDA has approved MMF 250 mg capsule (Mylan) as bioequivalent to CellCept®.  
Mylan compared their product to CellCept® in 32 fed and 34 fasting, healthy patients.  
Compared to that of CellCept® in the fasting state, Mylan reports their MMF product 
has an AUC0-t of 99%, AUCinfinity of 92%, and Cmax of 92%.  It is unclear if MMF 
(Mylan) reaches Cmax at the same time as CellCept® in RT patients, but is assumed to 
do so, as liberation of the drug is from a simple gelatin capsule.  But, if not, AUC 
calculators using a specimen time for Cmax other than 40 minutes may be warranted.
Measurement and comparison of  AUC was performed at time points around 60 days 
post-transplant or beyond.  This period coincides with our clinic protocol to check 
MMF AUC at day 60.  Also at this point, influences on MMF pharmacokinetics are 
minimized.  MMF AUC increases with time, which stabilizes once the prednisone dose 
is decreased to its maintenance dose, and renal function is stable (free fraction of drug 
normalizes).
We report that 4 of 6 patients had generic MMF AUC levels within 90% - 110% AUC 
to that of the innovator, and 5 of 6 patients had levels within 80 - 125%.  The number of 
patients included in this preliminary study is too small to perform any biostatistical
confirmation.  Additional RT patients should be evaluated to determine if these 
equivalency trends continue.  It is unclear if the differences we see between generic 
Table 1:  Patient renal function values on AUC measurement day
Patient CellCept® MMF (Mylan)
SCr mg/dL CrCl ml/min* SCr mg/dL CrCl ml/min*
1 1.03 51 1.11 47
2 0.99 59 0.98 60
3 0.91 55 0.89 57
4 1.11 65 1.24 58
5 1.32 52 1.27 54
6 0.98 79 0.97 81
*Cockcroft & Gault
daily.  MMF undergoes enterohepatic recirculation, making it difficult to conduct 
TDM using peak and/or trough drug levels alone.  MMF TDM using AUC may 
decrease risk of rejection as well as toxicity.  AUC is estimated via limited sampling 
strategy with MLR or BAY pharmacokinetic models.  These models are highly 
dependent on the pharmacokinetic properties of the innovator product, CellCept®.  A 
generic product with significant absorption and distribution characteristics could not 
be used with current MLR and BAY models.  The FDA approved 7 different generic 
forms of MMF between May 2008 and June 2009.  The FDA awards a 
bioequivalence rating (AB) to a drug if the manufacturer demonstrates that the 
generic product’s maximum concentration (Cmax) and AUC are both within 80-125% 
of the innovator.  Only a small, single-dose study in healthy patients is required to 
demonstrate bioequivalence in both fasting and fed states, with a 90% confidence 
interval.  It is unclear if bioequivalence would be determined in the renal transplant 
patient. We compare the AUCs of CellCept® vs. generic MMF (Mylan) in a fasting 
state using MLR and BAY models.
Conclusions
Compared to the limited sampling strategy MLR and BAY AUC of CellCept®:
• 4 of 6 patients had generic MMF AUC levels within 90% - 110%.
• 5 of 6 patients had generic MMF AUC levels within 80 - 125%.
MMF AUC monitoring is subject to a high degree of within-patient and between-patient 
variability.  We report our results on a small sample of our patient population.  It is 
unclear if the differences in AUC values between CellCept® and MMF (Mylan) are due 
to within-patient variability or true differences between the pharmacokinetic profiles of 
the 2 forms of MMF, which may limit the use of limited sampling AUC models.  AUC 
bioequivalence testing for larger groups of RT patients is warranted.  Current MLR and 
BAY models might not be applicable to patients taking generic MMF.
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MMF and innovator at day 60 will be exacerbated at time points closer to the surgical 
date when within-patient pharmacodynamics have more influence on AUC.
Methods
This study received approval from the Legacy Health System IRB. During the period 
of May 2009 to April 2010, we established an MMF TDM program utilizing MLR 
(using R 2.9.7) and Bayesian kinetics (using NONMEM). Six RT patients were 
prospectively enrolled in an non-randomized, open-label, crossover design study to 
compare MPA AUC of CellCept® to MPA AUC of a generic MMF formulation most 
often dispensed to our population (Mylan).  Patients used the 250mg strength capsule 
of each product.  Actual MMF doses varied at time of sampling as dictated by 
previous AUC monitoring.  Limited-sampling of MPA levels were drawn at 0, 40, 
and 240 minutes for patients taking tacrolimus (FK) or sirolimus (SRL), or 0, 40, and 
120 minutes for patients taking cyclosporine (CSA).  Patients consumed a minimum 
of 6 days of drug following the crossover before the subsequent AUC was collected.
Table 2:  MMF AUC results, using 250 mg capsule increments
Dose 
(mg)
CNI
Post-op 
Day
AUC
CellCept®
Post-op 
Day
AUC
MMF (Mylan)
BAY MLR BAY MLR
500 BID FK 201 47.25 61.14 208 38.02 48.89
750 BID FK 64 86.77* N/A* 71 88.57 112.81
1000 
BID
CSA 57 38.67 39.77 64 38.53 44.51
500 BID FK 67 28.86 35.18 74 36.1 47.02
1000 
BID
FK 56 61.72 67.95 63 55.01 63.85
750 BID SRL 82 28.52 35.16 76 43.82 62.87
* 240-minute sample not available (broken in transit)
